



ViroGates and Interlux Group will collaborate to market ViroGates' suPARnostic® products in the Baltic countries

23.1.2020 13:58:27 CET | ViroGates | Company Announcement

ViroGates A/S (Nasdaq First North Growth Market Denmark: VIRO), who delivers blood test products, primarily for emergency departments in hospitals, today announces that it has made a distribution agreement with Interlux Group based in Lithuania. The agreement grants Interlux the rights to distribute ViroGates' product range in the Baltic region. The Baltic region has approx. 180 hospitals.

Interlux Group is an international company operating from Vilnius, Lithuania and with a presence in the medical technology market for more than 25 years. Along with subsidiaries it supplies innovative, top-quality technologies and solutions for the medicine, science and biotechnology industry to customers in the Baltic region. Interlux distributes products from diagnostic companies such as Becton Dickinson, DiaSorin, QIAGEN etc. in all the Baltic states. It has a staff of more than 100 people.

CEO Jakob Knudsen, says in a comment: *"ViroGates is pleased to announce this collaboration with Interlux Group the leading supplier of diagnostic products in the Baltic region. We have been very happy with the insights and relations that Interlux have acquired. We have already met with a few hospitals in the Baltic countries and they have been very keen to implement our products, and we believe that this can be facilitated much stronger by ways of an experienced local player such as Interlux."*

CEO of Interlux Group, Dr. Audrius Matuzevicius says *"We are very happy to have signed an agreement with ViroGates and looking forward to the cooperation. suPARnostic® will from now on be available for the emergency medicine in the Baltics and we consider suPARnostic® a very good tool for supporting the Triage algorithm at the hospitals. We recently presented suPAR at the conference of Laboratory medicine in Vilnius, with a very positive feedback from the audience. Interlux see a very interesting potential in suPAR and are looking forward to implement it at the hospitals in our region"*

For further information contact:

CEO Jakob Knudsen

Tel. (+45) 2226 1355, Email: jk@virogates.com

ViroGates A/S - www.virogates.com

Interlux

Business Development Director Mr. Ignas Kamantauskas

Phone: +370 5 278 6850

E-mail: ignas.kamantauskas@interlux.lt

Website: www.interlux.lt

Certified Advisor

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, Email: per.lonn@vhcorp.se

About ViroGates

ViroGates is an international medtech company developing and marketing prognostics products to improve patient care, reduce healthcare costs and empower clinical staff in the healthcare sector. Based on more than 600 clinical trials and studies, ViroGates' suPARnostic® product range supports hospital professionals in making clinical decisions on hospitalization or discharge of acute care patients as well as detecting and assessing the severity of cardiovascular diseases, type 2 diabetes, cancer, etc. suPARnostic® TurbiLatex is available on Siemens ADVIA XPT instruments and Roche

Diagnostics' cobas instruments. ViroGates works with partners to develop solutions for other platforms. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Germany, Spain, and France, while distributors serve other markets.

This message can be found at <https://www.virogates.com/investor/announcements>

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

- Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com

Attachments

- [20200123 ViroGates Comp. ann 2.pdf](#)